A healthy gut may be a powerful ally in the fight against cancer, according to research recognized with the 2025 Bial Award in Biomedicine. An international team of 48 researchers has been awarded a €350,000 prize for a study demonstrating that the composition of bacteria in the human intestine – the gut microbiome – significantly influences the effectiveness of immunotherapy, a revolutionary cancer treatment. The findings, initially published in 2018 in the journal Science, suggest that maintaining a diverse and balanced gut microbiome could enhance a patient’s response to immunotherapy, while antibiotic employ may hinder its success. This groundbreaking function offers a new avenue for improving cancer treatment outcomes and understanding why some patients develop resistance to these therapies.
The study, titled “Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors,” was led by Laurence Zitvogel of Gustave Roussy and Paris-Saclay University, and Guido Kroemer of Gustave Roussy and Paris Cité University, both internationally renowned French academics. Their research sheds light on a critical factor often overlooked in cancer treatment: the complex ecosystem within our digestive systems. Understanding the interplay between the gut microbiome and immunotherapy is becoming increasingly important as these treatments become more widespread, offering hope to patients who previously had limited options. The award recognizes the exceptional quality and scientific relevance of their work in the field of biomedicine.
How the Gut Microbiome Impacts Immunotherapy
Immunotherapy works by essentially “re-arming” the body’s own immune system to recognize and attack cancer cells. However, more than half of patients treated with immunotherapy eventually develop resistance, leading to disease recurrence. Researchers have long sought to understand the reasons behind this resistance, and this study points to a key role played by the gut microbiome. The research team discovered that a diverse community of gut bacteria is associated with a more robust immune response to cancer treatment.
Specifically, the study showed that a greater diversity of bacterial species in the gut correlated with improved clinical outcomes in patients undergoing immunotherapy. The researchers identified specific bacterial species consistently linked to more favorable treatment responses, suggesting potential targets for future interventions. Conversely, the use of antibiotics, which can disrupt the delicate balance of the gut microbiome, was found to negatively impact the efficacy of immunotherapy. This finding underscores the importance of carefully considering antibiotic use in cancer patients undergoing immunotherapy.
The Role of Antibiotics and Gut Diversity
The negative impact of antibiotics on immunotherapy effectiveness is a significant finding. Antibiotics, while crucial for treating bacterial infections, can indiscriminately kill both harmful and beneficial bacteria in the gut, reducing overall microbial diversity. This disruption can weaken the immune system’s ability to respond to cancer treatment. The study highlights the need for strategies to protect and restore gut microbiome diversity in patients receiving immunotherapy, potentially through the use of probiotics, prebiotics, or fecal microbiota transplantation – though further research is needed to determine the optimal approaches.
Implications for Cancer Treatment and Future Research
The research, which has already garnered over 5,800 scientific citations since its publication in 2018, has significant implications for how cancer is treated. It suggests that assessing a patient’s gut microbiome composition could become a standard part of cancer care, helping doctors predict who is most likely to respond to immunotherapy and tailor treatment plans accordingly. Strategies to modulate the gut microbiome – such as dietary interventions or targeted probiotic therapies – could be used to enhance the effectiveness of immunotherapy and overcome resistance.
The Bial Award in Biomedicine, promoted by the Bial Foundation, recognizes exceptional contributions to biomedical research. The €350,000 prize will undoubtedly support further investigation into the complex relationship between the gut microbiome, and cancer. Researchers are now focused on identifying the specific mechanisms by which gut bacteria influence the immune system and developing personalized strategies to optimize the microbiome for cancer treatment. This area of research holds immense promise for improving the lives of cancer patients worldwide.
The findings underscore the growing understanding of the gut-brain-immune axis and the profound impact of the microbiome on overall health. As research continues, we can expect to see even more innovative approaches to harnessing the power of the gut microbiome to prevent and treat a wide range of diseases, including cancer. The next steps involve larger clinical trials to validate these findings and translate them into practical clinical applications.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this groundbreaking research? Share your comments below, and please share this article with anyone who might find it helpful.
